Abiomed-backed Shockwave Medical has raised approximately $97m in an oversubscribed initial public offering, before its shares climbed more than 85% by the end of Friday.

Shockwave Medical, a US-based calcification treatment system developer backed by medical implant manufacturer Abiomed, has secured $97m in an initial public offering on the Nasdaq Global Select Market. The company sold 5.7 million shares priced at $17 each, approximately 700,000 more than it had originally planned and above its target range of $14 to $16.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.